(Teva) resolving all patent litigation related to Axsome’s AUVELITY® (dextromethorphan HBr – bupropion HCl) product. The litigation resulted from submission by Teva of an Abbreviated New Drug ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a ...

Background: Dextromethorphan (DM), the d-isomer of ... extrapolated to suggest that pregnant women should not use this drug because of the risk of birth defects. We conducted a controlled study ...

Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Headquartered in Cupertino, California, the consumer electronics giant entered the smartphone market with the iPhone in 2007, and the tablet market with the iPad in 2010, and the smartwatch market ...

Founded in Beijing in 1984, Lenovo acquired IBM's PC business in 2005, and first became the world's top PC maker in 2013. It entered the Android and Windows tablet market in 2011, began selling ...

The settlement resolves all patent litigation related to Axsome’s Auvelity (dextromethorphan HBr – bupropion HCl ... Teva submitting an Abbreviated New Drug Application to the U.S. Food ...

Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...